Identification of small molecule activators of the Janus kinase/signal transducer and activator of transcription pathway using a cell-based screen

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 1, 2012, Pages 65-71

  Tai, Zheng Fu ^a   Zhang, Guo Lin ^a   Wang, Fei ^a  

^a CHENGDU INSTITUTE OF BIOLOGY   (China)

Author keywords

Emodin; Interferon; Janus kinase; Luteolin; Quercetin; Signal transducer and activator of transcription

Indexed keywords

ALPHA INTERFERON; APIGENIN; EMODIN; JANUS KINASE; LUCIFERASE; LUTEOLIN; QUERCETIN; STAT PROTEIN;

ANALYTIC METHOD; ARTICLE; CELL BASED SCREENING ASSAY; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG IDENTIFICATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PLASMID; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIVIRAL AGENTS; APIGENIN; DRUG EVALUATION, PRECLINICAL; EMODIN; FLAVONOIDS; GENE EXPRESSION; GENES, REPORTER; HEP G2 CELLS; HUMANS; INTERFERON TYPE I; JANUS KINASES; LUTEOLIN; PLANT EXTRACTS; QUERCETIN; RESPONSE ELEMENTS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; VIRUS DISEASES;

EID: 84862974919     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.65     Document Type: Article

References (27)

1. Grandvaux N, tenOever BR, Servant MJ, Hiscott J. The interferon antiviral response: from viral invasion to evasion. Curr. Opin. Infect. Dis., 15, 259-267 (2002).
2. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol., 5, 375-386 (2005).
3. Schindler C, Darnell JE Jr. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem., 64, 621-651 (1995).
4. Shuai K, Liu B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol., 3, 900-911 (2003).
5. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer, 4, 97-105 (2004).
6. Papageorgiou AC, Wikman LEK. Is JAK3 a new drug target for immunomodulation-based therapies? Trends Pharmacol. Sci., 25, 558-562 (2004).
7. Richman DD. Antiviral drug resistance. Antiviral Res., 71, 117-121 (2006).
8. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist, 6, 34-55 (2001).
9. Tian SS, Lamb P, King AG, Miller SG, Kessler L, Luengo JI, Averill L, Johnson RK, Gleason JG, Pelus LM, Dillon SB, Rosen J. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor [see comments]. Science, 281, 257-259 (1998).
10. Zhang B, Salituro G, Szalkowski D, Li ZH, Zhang Y, Royo I, Vilella D, Díez MT, Pelaez F, Ruby C, Kendall RL, Mao XZ, Griffin P, Calaycay J, Zierath JR, Heck JV, Smith RG, Moller DE. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science, 284, 974-977 (1999).
11. Sato A, Sone S. A peptide mimetic of human interferon (IFN)-beta. Biochem. J., 371, 603-608 (2003).
12. Lynch RA, Etchin J, Battle TE, Frank DA. A small-molecule enhancer of signal transducer and activator of transcription 1 transcriptional activity accentuates the antiproliferative effects of IFNgamma in human cancer cells. Cancer Res., 67, 1254-1261 (2007).
13. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov., 4, 206-220 (2005).
14. Zhang JH, Chung TDY, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen., 4, 67-73 (1999).
15. Seidel HM, Lamb P, Rosen J. Pharmaceutical intervention in the JAK/STAT signaling pathway. Oncogene, 19, 2645-2656 (2000).
16. Shuangsuo D, Zhengguo Z, Yunru C, Xin Z, Baofeng W, Lichao Y, Yan'an C. Inhibition of the replication of hepatitis B virus in vitro by emodin. Med. Sci. Monit., 12, BR302-BR306 (2006).
17. Lin CW, Wu CF, Hsiao NW, Chang CY, Li SW, Wan L, Lin YJ, Lin WY. Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int. J. Antimicrob. Agents, 32, 355-359 (2008).
18. Blank VC, Poli C, Marder M, Roguin LP. Antiproliferative activity of various flavonoids and related compounds: additive effect of interferon-α2b. Bioorg. Med. Chem. Lett., 14, 133-136 (2004).
19. Aalinkeel R, Bindukumar B, Reynolds JL, Sykes DE, Mahajan SD, Chadha KC, Schwartz SA. The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate, 68, 1773-1789 (2008).
20. Proia DA, Foley KP, Korbut T, Sang J, Smith D, Bates RC, Liu YA, Rosenberg AF, Zhou D, Koya K, Barsoum J, Blackman RK. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS ONE, 6, e18552 (2011).
21. Liu AL, Liu B, Qin HL, Lee SMY, Wang YT, Du GH. Anti-influenza virus activities of flavonoids from the medicinal plant Elsholtzia rugulosa. Planta Med., 74, 847-851 (2008).
22. Sternberg Z, Chadha K, Lieberman A, Drake A, Hojnacki D, Weinstock- Guttman B, Munschauer F. Immunomodulatory responses of peripheral blood mononuclear cells from multiple sclerosis patients upon in vitro incubation with the flavonoid luteolin: additive effects of IFN-β. J. Neuroinflammation, 6, 28 (2009).
23. Shi RX, Ong CN, Shen HM. Protein kinase C inhibition and X-linked inhibitor of apoptosis protein degradation contribute to the sensitization effect of luteolin on tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in cancer cells. Cancer Res., 65, 7815-7823 (2005).
24. Du ZM, Shen YH, Yang WT, Mecklenbrauker I, Neel BG, Ivashkiv LB. Inhibition of IFN-alpha signaling by a PKC- and protein tyrosine phosphatase SHP-2-dependent pathway. Proc. Natl. Acad. Sci. U.S.A., 102, 10267-10272 (2005).
25. Hilkens CMU, Schlaak JF, Kerr IM. Differential responses to IFN-alpha subtypes in human T cells and dendritic cells. J. Immunol., 171, 5255-5263 (2003).
26. van Boxel-Dezaire AHH, Rani MRS, Stark GR. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity, 25, 361-372 (2006).
27. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon- alpha/beta revisited. Nat. Rev. Mol. Cell Biol., 2, 378-386 (2001).